Verseon
To advance global health, Verseon International Corporation (http://www.verseon.com) has created a better, more scalable process for designing and developing new drugs addressing currently untreatable or poorly treated conditions. The company's drug development platform incorporates fundamental advancements in molecular modeling, directed synthesis, integrated translational research and AI to develop drug compounds that have never before been synthesized-and are virtually impossible to find using conventional methods. Verseon is a clinical-stage company with a growing pipeline that currently includes seven drug programs in the areas of anticoagulation, diabetic retinopathy, hereditary angioedema, oncology, and metabolic disorders.